BioPharma Clinical Trials: Gene Therapy, Obesity, and Oncology Updates
Updates on gene therapy, oncology, and obesity treatments were presented this week, including Benitec Biopharma's BB-301 for OPMD and Boehringer Ingelheim's survodutide for obesity.
Key Takeaways
- Benitec Biopharma's BB-301 shows promising interim Phase 1b/2a results for OPMD, presented at ASGCT 2026.
- FDA clears Cellenkos' CK0801 for Phase II trials in aplastic anemia, building on durable transfusion independence seen in Phase I.
- AstraZeneca and Amgen trials utilize real-time data monitoring via Paradigm Health to accelerate phase transitions.
- Boehringer Ingelheim's survodutide demonstrates 'Wegovy-like' weight loss with potential muscle preservation benefits.
This week in biopharma clinical trials, several companies announced key updates in gene therapy, oncology, and obesity treatments. Highlights include interim results from Benitec Biopharma's BB-301 for oculopharyngeal muscular dystrophy (OPMD), the FDA clearance of Cellenkos' CK0801 for a Phase II trial in aplastic anemia, and promising Phase 3 data for Boehringer Ingelheim's survodutide in obesity. These advancements were showcased during the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting in Boston.
The biopharmaceutical sector continues to push boundaries with innovative approaches to address unmet medical needs. Gene therapy is showing promise in rare diseases, while oncology trials are leveraging real-time data to improve efficiency. The obesity market is also seeing new entrants with potentially differentiated benefits.
Gene Therapy Updates
Benitec Biopharma BB-301 (OPMD): Benitec Biopharma presented interim Phase 1b/2a results for BB-301, a gene therapy for oculopharyngeal muscular dystrophy (OPMD), at the ASGCT 2026 Annual Meeting on May 15, 2026. The presentation included 12-month post-treatment follow-up data for the first four Cohort 1 completers and 24-month follow-up data for one Cohort 1 patient. BB-301 is the only clinical-stage therapeutic in development for dysphagia in OPMD patients.
Cellenkos CK0801 (Aplastic Anaemia): The FDA has cleared Cellenkos' CK0801 for Phase II clinical trials in aplastic anemia. The open-label, multi-center trial will evaluate the safety and clinical activity of CK0801 in adults who are refractory to prior therapy, intolerant to standard treatments, or transfusion-dependent. Phase I data published in *NEJM Evidence* (2024) showed durable transfusion independence up to 3.5 years in individual patients.
Oncology Trials with Real-Time Monitoring
AstraZeneca & Amgen FDA Pilot: The FDA announced real-time data monitoring for two Phase trials effective April 28, 2026:
- AstraZeneca Phase 2 (lymphoma): An aggressive lymphoma combination therapy trial at UT MD Anderson Cancer Center and the University of Pennsylvania.
- Amgen Phase 1b (small cell lung carcinoma): A treatment trial for small cell lung carcinoma.
Both trials utilize Paradigm Health's real-time data platform to accelerate phase transitions.
Obesity Drug Results
Boehringer Ingelheim Survodutide: Boehringer Ingelheim's survodutide, a dual-acting obesity shot licensed from Zealand Pharma, demonstrated Phase 3 success with "Wegovy-like" weight loss while showing potential muscle-mass preservation benefits.
Early-Stage Programs
Coultreon Biopharma COL-5671 (TNFΞ± inhibitor): Coultreon Biopharma raised $125M for the advancement of its SIK inhibitor, COL-5671. Phase 1 preliminary results presented in February 2026 showed TNFΞ± inhibition comparable to monoclonal antibodies, with sustained inhibition >90% at 24 hours for the 15 mg dose.
Sangamo Therapeutics SKG0201 (SMA Type I): Sangamo Therapeutics' SKG0201, a treatment for spinal muscular atrophy (SMA) Type I, is currently in a Phase I/II study (NCT07554924), which is actively recruiting.
ASGCT 2026 Presentations
The ASGCT 2026 Annual Meeting featured several presentations on preclinical and early clinical gene/cell therapy data.
- Asgard Therapeutics: Presented preclinical data on AT-108, an off-the-shelf gene-based cancer immunotherapy. Monotherapy doubled median survival, and combination with immune checkpoint blockade (ICB) achieved 50% complete responses in a B16 model.
- Benitec Biopharma: Presented interim Phase 1b/2a results for BB-301, a gene therapy for OPMD, showing durable swallowing improvements.
- Azitra: Presented preclinical data on ATR-01 for Ichthyosis Vulgaris, demonstrating delivery of functional filaggrin and restoration of the skin barrier.
Frequently Asked Questions
- What is BB-301?
- BB-301 is a gene therapy developed by Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy (OPMD), specifically targeting dysphagia (difficulty swallowing).
- What is CK0801?
- CK0801 is a cell therapy developed by Cellenkos for the treatment of aplastic anemia. It is currently cleared for Phase II clinical trials.
- What is survodutide?
- Survodutide is a dual-acting obesity shot developed by Boehringer Ingelheim, licensed from Zealand Pharma. It has shown promising results in Phase 3 trials, demonstrating weight loss and potential muscle mass preservation.
- What is Paradigm Health's role in oncology trials?
- Paradigm Health provides a real-time data platform used in oncology trials by companies like AstraZeneca and Amgen to accelerate phase transitions.
- What is ASGCT?
- ASGCT stands for the American Society of Gene and Cell Therapy. It is a professional non-profit organization committed to advancing knowledge, awareness, and education in gene and cell therapy.
References
- Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 at ASGCT 2026
- Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
- Cellenkosβ CK0801 gets FDA nod for Phase II trial in aplastic anaemia
- FDA to test real-time data monitoring in clinical trials for cancer drugs from AstraZeneca and Amgen
- biochempeg.com
- Boehringer Ingelheim's Survodutide Shows 'Wegovy-Like' Weight Loss
- Asgard Therapeutics Announces Oral Presentation at ASGCT 2026 Showcasing Advanced Preclinical Data on AT-108
- Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
- Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026
